{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-059461","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.021182+00:00","generated_at":"2026-06-08T21:09:29.384974+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CRISPR Q3 net loss narrows; exa-cel PDUFA: Dec 8 (SCD) & Mar 30, 2024 (TDT)","bullets":["PDUFA target action date for exa-cel in sickle cell disease: Dec 8, 2023; for beta thalassemia: March 30, 2024.","Net loss narrowed to $112.2M in Q3 2023 from $174.5M in Q3 2022; cash $1.74B.","R&D expenses decreased to $90.7M from $116.6M; G&A down to $18.3M from $27.0M.","Initiated Phase 1 trial for CTX310 targeting ANGPTL3; CTX320 on track for clinic in H1 2024.","Proposed election of Sandy Mahatme to Board at 2024 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-059461","json":"https://secwatch.observer/filing/0000950170-23-059461.json","markdown":"https://secwatch.observer/filing/0000950170-23-059461.md","text":"https://secwatch.observer/filing/0000950170-23-059461.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023059461/0000950170-23-059461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023059461/crsp-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:09:29.384974+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b98250d1be4d4363d0121698f919e1f8f1d4f014","claim":"CRISPR Therapeutics AG reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023059461/0000950170-23-059461-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}